---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-24-000231"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2024-12-20T23:59:59+00:00"
generated_at: "2026-05-29T00:44:17.955605+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vertex receives FDA approval for new CF drug ALYFTREK; wholesale cost $370K/year

## Summary
- FDA approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) for CF in patients 6+ years with at least one F508del mutation.
- Annual wholesale acquisition cost in the U.S. is $370,269 ($28,404 per 28-day pack).
- Approval expands Vertex's cystic fibrosis treatment portfolio.

## SEC filing metadata
- accession: 0000875320-24-000231
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2024-12-20T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532024000231/0000875320-24-000231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532024000231/vrtx-20241220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-24-000231
- JSON: https://secwatch.observer/filing/0000875320-24-000231.json
- Plain text: https://secwatch.observer/filing/0000875320-24-000231.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.